Case todayNot read todayThesis-Break EngineThe case · mixed · Nov 16, 2026Own IPSC if Century Therapeutics is a high-risk platform biotech whose value depends on proving that allogeneic pluripotent stem-cell therapies can become partnered, clinically validated products before cash burn forces dilution.5 conditions4 holding · 1 weakeningNext resultsMar 11, 2027Projected from its filing dates

IPSC at a glance

The past year

Chart

+190.3% $1.37, close Nov 17

From the highest close
−53.4%
Vs the 200-day average
−33.5%
Nov 14, 2025Daily close, Century TherapeuticsNov 17, 2026

Short interest

History

32.0M shares

Of shares outstanding
17.6%
Since the last report
+9.9%
Days to cover
31 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 12 – Nov 18

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

IPSC price history

Latest price$1.37Today−$0.27 (-16.46%)
IPSC -4.20%S&P 500 -4.78%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Century’s off-the-shelf pluripotent stem-cell platform remains partner-worthy because it addresses the scalability limits of autologous cell therapy; that only matters if collaboration or contract economics recur rather than appearing as a one-time accounting event.HoldingMateriality: High

    GAAP annual revenue increased from $6.589 million in FY2024 to $109.164 million in FY2025. If partner demand persists, non-dilutive capital can fund the pipeline; if it fades, shareholders must finance expensive cell-therapy R&D themselves.

    Watch: Existing or prospective pharmaceutical partners terminate, pause, or decline new iPSC/allogeneic cell-therapy collaborations after reviewing data.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue increased from $6.589 million in FY2024 to $109.164 million in FY2025.

    Open source ↗
  • Cash runway is the gating strategic constraint, so Century must either reduce burn, raise non-dilutive capital, or sequence programs tightly enough to avoid financing the whole platform through distressed equity.WeakeningMateriality: High

    Cash and cash equivalents were $61.853 million at FY2025 year-end. The same science can be worth far less per share if it requires repeated dilutive financings before proof of concept.

    Watch: Clinical trial expansion, manufacturing scale-up, or CMC remediation increases cash needs before new milestones arrive.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash and cash equivalents were $61.853 million at FY2025 year-end.

    Open source ↗
  • Century’s lean organization must be capable of advancing complex cell-therapy development through focused execution and external leverage; if the platform requires broad internal manufacturing and clinical infrastructure, the model becomes under-resourced.HoldingMateriality: Medium

    The company reported 78 full-time employees as of March 1, 2026. A small team can be efficient if the platform is modular and partnered, but it becomes a constraint if each program needs bespoke infrastructure.

    Watch: Manufacturing comparability, release testing, or scale-up problems require a major internal buildout.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The company reported 78 full-time employees as of March 1, 2026.

    Open source ↗
  • The path to improved economics depends on high-value collaboration or milestone revenue absorbing the fixed cost base; without repeat partner payments, operating losses will revert toward the underlying R&D burden.HoldingMateriality: Medium

    GAAP annual operating loss improved to $17.269 million in FY2025 from $138.137 million in FY2024. This determines whether Century can fund value-creating development internally or remains dependent on external financing.

    Watch: FY2025 revenue proves to be a non-recurring payment with no follow-on milestones or new collaborations.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating loss improved to $17.269 million in FY2025 from $138.137 million in FY2024.

    Open source ↗
  • A lighter liability load gives Century some negotiating flexibility, but that advantage disappears if new obligations or financing claims are added before the platform is clinically de-risked.HoldingMateriality: Medium

    Total liabilities declined from $191.854 million at FY2024 year-end to $64.768 million at FY2025 year-end. Lower balance-sheet encumbrance can preserve upside for common shareholders; new senior claims can transfer future platform value away from equity.

    Watch: The company takes on secured debt, royalty financing, or onerous manufacturing commitments to fund trials.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Total liabilities declined from $191.854 million at FY2024 year-end to $64.768 million at FY2025 year-end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Century’s off-the-shelf pluripotent stem-cell platform remains partner-worthy because it addresses the scalability limits of autologous cell therapy; that only matters if collaboration or contract economics recur rather than appearing as a one-time accounting event. If partner demand persists, non-dilutive capital can fund the pipeline; if it fades, shareholders must finance expensive cell-therapy R&D themselves.

Cash runway is the gating strategic constraint, so Century must either reduce burn, raise non-dilutive capital, or sequence programs tightly enough to avoid financing the whole platform through distressed equity. The same science can be worth far less per share if it requires repeated dilutive financings before proof of concept.

Century’s lean organization must be capable of advancing complex cell-therapy development through focused execution and external leverage; if the platform requires broad internal manufacturing and clinical infrastructure, the model becomes under-resourced. A small team can be efficient if the platform is modular and partnered, but it becomes a constraint if each program needs bespoke infrastructure.

The path to improved economics depends on high-value collaboration or milestone revenue absorbing the fixed cost base; without repeat partner payments, operating losses will revert toward the underlying R&D burden. This determines whether Century can fund value-creating development internally or remains dependent on external financing.

A lighter liability load gives Century some negotiating flexibility, but that advantage disappears if new obligations or financing claims are added before the platform is clinically de-risked. Lower balance-sheet encumbrance can preserve upside for common shareholders; new senior claims can transfer future platform value away from equity.

All standing thesis claims
Original report summary

Century Therapeutics is a high-risk platform biotech whose value depends on proving that allogeneic pluripotent stem-cell therapies can become partnered, clinically validated products before cash burn forces dilution.

Evidence assessed Nov 16, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Century Therapeutics

Where the evidence on Century Therapeutics disagrees: Mixed on the latest evidence (Nov 16, 2026). Of its 5 thesis points, 4 holding and 1 weakening.

Bull case: what the evidence supports

  • Century’s off-the-shelf pluripotent stem-cell platform remains partner-worthy because it addresses the scalability limits of autologous cell therapy; that only matters if collaboration or contract economics recur rather than appearing as a one-time accounting event.

    sec.gov ↗

  • Century’s lean organization must be capable of advancing complex cell-therapy development through focused execution and external leverage; if the platform requires broad internal manufacturing and clinical infrastructure, the model becomes under-resourced.

    sec.gov ↗

  • The path to improved economics depends on high-value collaboration or milestone revenue absorbing the fixed cost base; without repeat partner payments, operating losses will revert toward the underlying R&D burden.

    sec.gov ↗

  • A lighter liability load gives Century some negotiating flexibility, but that advantage disappears if new obligations or financing claims are added before the platform is clinically de-risked.

    sec.gov ↗

Bear case: what the evidence questions

  • Cash runway is the gating strategic constraint, so Century must either reduce burn, raise non-dilutive capital, or sequence programs tightly enough to avoid financing the whole platform through distressed equity.

    sec.gov ↗

Company research

Research on Century Therapeutics

Thesis-Break Engine

Thesis-break watch · Century Therapeutics

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Century Therapeutics’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Century Therapeutics filed an SEC 8-K on 2026-11-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Regulation FD disclosure.

    Century Therapeutics filed an SEC 8-K on 2026-10-02: Regulation FD disclosure. It is a dated development that tests the current thesis.

  3. Mixed
    Director or principal officer change.

    Century Therapeutics filed an SEC 8-K on 2026-09-09: Director or principal officer change. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Existing or prospective pharmaceutical partners terminate, pause, or decline new iPSC/allogeneic cell-therapy collaborations after reviewing data.
  • Clinical trial expansion, manufacturing scale-up, or CMC remediation increases cash needs before new milestones arrive.
  • Manufacturing comparability, release testing, or scale-up problems require a major internal buildout.
  • FY2025 revenue proves to be a non-recurring payment with no follow-on milestones or new collaborations.
  • The company takes on secured debt, royalty financing, or onerous manufacturing commitments to fund trials.

IPSC news

Loading headlines…

Financial statements

IPSC income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

IPSC: quick answers

When does Century Therapeutics (IPSC) report earnings next?
Century Therapeutics's next results are projected for March 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 12, 2026. Earnings calendar
What is IPSC's short interest?
As of October 30, 2026, 32.0M IPSC shares were sold short, 17.6% of its shares outstanding, up 9.9% from the count before. At the stock's average daily volume that is 31 days to cover. FINRA publishes the count twice a month. IPSC short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.